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ABSTRACT 
 Poor water-solubility is becoming the leading hurdle for novel drug molecules to reach 
the market. Enhancing the surface-to-volume ratio by reducing the drug particles size has 
emerged as a powerful method to enhance the drug dissolution rate of poorly water-soluble 
drugs. Here we present several approaches to produce micro- and nano-suspensions of febantel 
and itraconazole, as poorly water-soluble model drugs, in the presence of the self-emulsifying 
excipient Gelucire 44/14 as additional solubility enhancing agent. Two top-down approaches 
involving either ball milling or ultrasound treatment, to reduce the size of existing drug crystals, 
were used as reference processes. Both techniques allowed to significantly reduce the size of 
the drug crystals and enhance the dissolution of febantel with the ultrasound treated 
formulation performing the best. In case of itaconazole, no influence of both processing 
techniques was observed, which is likely to be attributed to its extremely low water-solubility. 
To address this challenge, we developed a novel bottom up approach to produce 
nanosuspensions. This approach involved first dissolving the drug in molten Gelucire 44/14 
followed by atomization into cold water. During the atomization, cavitation was induced by 
ultrasonication. This process yielded milky suspensions in the submicrometer range. 
Furthermore a fraction of the drug was found to be in amorphous state. Nanosuspensions 
produced by this technique showed improved dissolution behavior, both in case of febantel and 
itraconazole. 
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1. INTRODUCTION  
One of the major causes of new drug molecules failing to reach the market is poor 
bioavailability. Indeed, many of the newly discovered drug candidates suffer from low to 
extremely low water solubility and hence are prone to limited bioavailability. [1-3] To cope with 
these issues, drug formulation scientists are developing formulation strategies that enhance the 
dissolution, and thus bioavailability of these poorly water-soluble drugs. [4-10] These strategies 
include, formation of inclusion complexes with cyclodextrins, using amphiphillic excipients such 
as block copolymer micelles, formulation in lipids, salt formation, transformation of crystalline 
to amorphous, particle size reduction, etc...  
Amongst these techniques, particle size reduction is highly promising. [9-10] 
Micronization of drug crystals to the lower micron range improves drug dissolution by various 
mechanisms. [11] According to the Noyes-Whitney equation, the dissolution rate increases by 
increasing the specific surface area. Decreasing the particles size also increases the saturation 
solubility according to the Ostwald-Freundlich equation. Furthermore, the Prandtl equation 
predicts that a decrease in particle size will results in a thinned hydrodynamic layer around the 
particles and an increase of the surface-specific dissolution rate. For the simplified case of 
spherical particles, size reduction with a factor 10 (e.g from 100 µm to 10 µm), a 100-fold 
increase in surface area is obtained. However, for extremely hydrophobic drug molecules, 
micronization is not sufficient to achieve high enough bioavailability [12,13]. Therefore, 
reducing particle size to the nanorange (increasing the surface area of the drug crystals with 
multiple orders of magnitude) has been investigated through several approaches. Basically, 
these can be divided into two main groups: top-down and bottom-up techniques. In a top-down 
approach, nanoparticles are produced by exposing drug particles to mechanical energy, either 
through impact, shear or ultrasound induced cavitation. Drawbacks of these approaches are the 
limited control over the final particle size and morphology and the risk for potential 
contamination originating from the grinding media or ultrasonication set-up. Bottom-up 
approaches involve controlled recrystallization of dissolved (typically in organic solvents) drug 
molecules into nanoparticles via e.g. spray-drying or solvent-displacement. These approaches 
allow, by optimizing solvent and stabilizer (e.g. surfactants) a better control over particle size 
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and morphology. However, a major drawback is the use of organic solvents that holds the risk of 
residual traces of organic solvents that can hardly be removed. 
When producing crystalline drug nanosuspensions, several considerations should be 
taken into account. First of all, colloidal stability of the nanosuspension is an important issue as 
reaggregation of hydrophobic nanocrystals readily takes place when these are not stabilized by 
means of surface active molecules. Reaggregation decreases the total drug surface area, 
thereby decreasing drug dissolution kinetics and should thus be avoided. Secondly, Ostwald 
ripening which involves the dissolution of smaller particles in favour of the growth of larger ones 
should be avoided. Third, drug concentration plays an important role as for practical reasons 
excessive dilution of the nanosuspensions should be limited. Related to the latter is the further 
processing of the nanosuspensions into a solid form, while still allowing a nanosuspension to 
reform in aqueous physiological medium (e.g. in the gastrointestinal tract). 
This study aims to evaluate different solvent-free approaches to produce 
nanosuspensions of poorly water-soluble drugs in order to enhance their dissolution behaviour. 
As model drugs, itraconazole (Figures 1A); and febantel (Figures 1B) were chosen due to their 
extremely low water solubility. In order to stabilize the drug nanosuspensions, we will 
coformulate the drug nanocrystals with non-ionic surfactants. First we present two top-down 
approaches based on either simple grinding or ultrasonic treatment of crystalline drug 
suspended in liquid surfactant. In the bottom-up approach, drug dissolved in a liquid surfactant 
is atomized in water under ultrasonic cavitation to control the size of the formed drug 
precipitates. Cavitation is the formation of gas bubbles in a liquid phase in regions where the 
pressure of the liquid falls below its vapour pressure. Due to acoustic waves, the gas bubbles 
oscillate in size and upon collapse of the bubbles, a shock wave is produced. These shock waves 
have sufficient power to erode crystalline material into smaller particles as well as avoiding 
nanoparticle aggregation. [14] 
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2. MATERIALS AND METHODS 
2.1 Materials 
Febantel was obtained from Fagron (Belgium) and itraconazole was obtained from 
Johnson & Johnson (Belgium). To allow proper comparison between the different formulations 
we have determined the solubility of both drug molecules experimentally under the same 
conditions as those that will be used for dissolution experiments, i.e. 0.1 M HCl and 37 °C. These 
values were found to be respectively 0.51 ± 0.05 mg/mL for febantel and 0.0012 ± 0.007 mg/mL 
for itraconazole. Figure 1 shows the molecular structure of both drugs. Febantel is a broad-
spectrum probenzimidazole that is widely used against gastrointestinal nematodes and lung 
worms in live stock [15-19]. It is a prodrug that is metabolized in vivo to fenbendazole and 
further to oxfendazole, 4-hydroxyfembendazole, 4-hydroxyfendazole, and an inactive 
metabolite febendazolesulfone [20-25]. Itraconazole is a triazole antifungal drug, used in the 
treatment of fungal infections. 
Gelucire 44/14 (i.e. PEG-32 glyceryllaurate) was obtained from Gattefossé (France). 
Gelucire 44/14 is an amphiphilic semisolid with a melting point of 44 °C and an HLB of 14. 
Gelucire 44/14 is GRAS (generally recognized as safe) and is obtained by polyglycolysis of 
hydrogenated palm kernel oil with polyethylene glycol 1500. Due to its unique composition, 
comprising mono- and diesters of PEG, mono-, di- and triglycerides, it spontaneously forms a 
microemulsion upon contact with water [26]. These properties allow Gelucire 44/14 to be used 
in the solubilization enhancement of poorly soluble drugs and increase of their solubility rate 
[27, 28]. 
 
2.2 Preparation of the nanosuspensions 
The composition of the nanosuspensions containing itraconazole and febantel is 
displayed in Table 1. 
 
2.2.1.  Wet milling 
Drug, Gelucire 44/14 and water were added to a 500 mL zirconium dioxide grinding bowl 
loaded with 25 zirconium dioxide grinding beads of 20 mm in diameter. The bowl was closed 
with a zirconium dioxide lid, placed in a ball mill type Pulverisette 6 (Fritsch, Idar-Oberstein, 
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Germany) and allowed to rotate at 350 rpm for respectively 15, 30, 45 and 60 min. For further 
dissolution experiments, we used samples that were milled for 60 min.  
2.2.2 Indirect sonication  
First, Gelucire 44/14 was dispersed in water followed by the addition of the crude 
crystalline drug powder. The experimental set-up is schematically shown in Figure 2. The 
ultrasonic mini flow cell was obtained from Hielscher Ultrasonics (Teldow, Germany) and 
attached to a titanium sonotrode type BS2d22 (HielscherUltrasonics) and an ultrasound 
generator type UIP1000 (Hielscher Ultrasonics), operating at 20 kHz (± 1kHz) and an intensity of 
20 W/cm².  The ultrasonic mini flow cell consists of a glass tube connected to a closed tubing 
circuit in which the aqueous drug/Gelucire 44/14 suspension is injected through a syringe 
connected to a valve. Table 1 shows the composition of the starting suspension. From this 30 
mL was injected into the system. The tubing is inserted in a peristaltic pump to allow circulation 
of the suspension at a flow rate of 30 mL/min. The residence time of the suspension in the flow 
cell can be controlled via the peristaltic pump. Additionally, the ultrasonic mini flow cell 
contains a water jacket (room temperature), surrounding the glass tube (4 mm in diameter), 
connected with a pressurized water reservoir. This water jacket allows propagation of the 
generated ultrasonic waves, transmitting them to the suspension within the glass tube. 
Furthermore, the water jacket allows controlling the temperature of the glass tube limiting the 
heating caused by the ultrasonication. Samples were prepared that were processed for 
respectively 30, 60, 90 and 120 min. Those subjected to 120 min of processing were used for 
dissolution experiments.  
 
2.2.3 Ultrasonic melt precipitation 
Figure 3 shows a schematic representation of the experimental set-up to produce drug 
nanosuspensions via ultrasonic melt precipitation. Itraconazole and febantel were first dissolved 
in Gelucire 44/14 at respectively 150°C and 140°C, which is above their respective melting point. 
Subsequently, the liquid phase was atomized at an air pressure of 5 bar through a 2 fluid nozzle 
into a dual wall stainless steel flow cell containing 150 mL water. The flow rate was 4 mL/min for 
tfebantel suspensions and 6 mL/min for itraconazole suspensions. The water was 
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thermostatized at 10°C to allow prompt cooling of the atomized liquid. The temperature was 
monitored by an in line temperature probe. During the atomization process, cavitation was 
induced to the system by means of an ultrasonic probe (HielscherUltrasonics, Teldow, Germany) 
composed of a titanium sonotrode type BS2d22 (HielscherUltrasonics), a booster type B2-1.4 
(HielscherUltrasonics) and an ultrasound generator type UIP1000 (HielscherUltrasonics) 
operating at 20 kHz ± 1 kHz, and an intensity of 100W/cm2. After 5 minutes of sonication, milky 
suspensions of both drugs were obtained and used for particle size measurements and 
dissolutions experiments.  
 
2.3 Particle size distribution 
The particle size distribution of the drug crystals in the nanosuspensions was determined 
by laser diffraction using a Malvern Mastersizer S (Malvern Instruments, Spring Lane South, UK) 
equipped with a small volume dispersion unit and a 300 RF lens. Water was used as dispersion 
medium for all measurements. 
 
2.4 Optical microscopy 
Optical microscopy images were recorded under brightfield and polarized light using a 
Leica 2500P microscope equipped with 10x and 63x oil-immersion objectives, a DFC360FX CCD 
camera and a Linkham THMS600 heating stage. To allow proper visualization, drug crystals and 
nanosuspensions were squeezed between two glass cover slides. 
 
2.6 In vitro drug dissolution 
Drug release from the produced nanosuspensions was evaluated in a VK7010 dissolution 
bath (VanKel Industries, NJ, USA) equipped with a VK8000 automatic sampling station (VanKel 
Industries, NJ, USA). All dissolution tests were run in triplicate. Note that since this study 
focused on the development of formulations that enhanced the dissolution rate of extremely 
poorly water-soluble drugs, sink conditions were not met. As dissolution medium, 900 ml 0.1 M 
HCl in demineralized water was used at a temperature of 37°C. At 5, 10, 15, 20, 30, 45 and 60 
minutes, 5 ml samples were withdrawn from the dissolution vessels without medium 
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replacement, filtered through a 200 nm filter to remove particulate matter and analyzed by 
spectrophotometry for their drug content. The febantel concentration was measured at 280 nm 
and itraconazole concentration was measured at 260 nm using a double beam 
spectrophotometer (Shimadzu UV-1650 PC, Shimadzu CO., Kyoto, Japan). It was verified that 
Gelucire 44/14 did not interfere with neither febantel nor itraconazole at the respective 
wavelengths used to determine the drug concentration. The  analytical methods were validated 
according to the ICH Harmonized Tripartite Guideline – Validation of Analytical Procedures 
(1994). 
 
2.7 X-ray diffraction (XRD) 
X-ray diffractograms were recorded on a PANalytical X'Pert PRO X-ray diffractometer (Siemens). 
XRD patterns were obtained with Cu KR radiation (45 kV x 40 mA; λ = 1.5406 A) at a scanning 
speed of 25° (2θ)/min and step size of 0.03° (2θ). Measurements were done in the reflection 
mode in the 2θ range of 5-40°.  
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3.  RESULTS AND DISCUSSION 
3.1  Preparation of nanosuspensions 
 As mentioned above, itraconazole and febantel are used in this study as model poorly 
water-soluble drugs. Both drugs are highly crystalline with a mean diameter D(v, 0.5) of 
respectively 26 µm (itraconazole) and 232 µm (febantel) as measured by laser diffraction. A first 
step in our formulation strategy was suspending the crystalline drug in Gelucire 44/14 and 
water. The rationale behind this is to use Gelucire 44/14 as a biocompatible surface-active agent 
that would aid in the formation of nanosuspensions by covering newly formed particle surface, 
preventing immediate re-aggregation. A first series of preliminary screening experiments served 
to determine the Gelucire 44/14 to drug ratio that allows processing via all three formulation 
processes. The respective formulation parameters are shown in Table 1.  
 
3.1.1 Wet milling 
 Wet milling is frequently used to produce drug nanosuspensions, and was used in this 
work as reference process. The crude aqueous drug/Gelucire 44/14 suspensions were added to 
a bowl containing zirconium dioxide as grinding medium, and were subsequently placed during 
1 h in a ball mill at 350 rpm. Figure 4A, shows the evolution of the particle size distribution and 
the mean particle diameter, measured by laser diffraction, during the wet milling process. These 
data demonstrate that for both febantel and itraconazole the initial particle population 
decreases as a function of process time, while a new sub-micron population emerges. Although 
efficient to produce drug nanosuspensions, the wet milling process bears several disadvantages. 
First of all, relatively long milling times are required. Secondly, there is a potential risk of 
contaminating the drug formulation with particulate matter resulting from erosion of the milling 
components. A third limitation is the possibility of only batch wise production. 
. 
3.1.2 Indirect sonication 
 To cope with the above mentioned issues related to wet milling, we aimed to design a 
process that allows to generate energy input without exposing the drug molecules to potential 
sources of contamination. Therefore, we constructed in-house an ‘indirect sonication’ set-up. 
An advantageous aspect of this process the shielding of the suspensions from the sonication tip 
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by a glass wall. This prevents contamination by eroded metal nanoparticles from the sonication 
time after prolonged processing times. Additionally,  this process can potentially be operated in 
continuous fashion by putting multiple sonication cells in series.  
 Figure 5 displays the evolution of the particle size, measured by laser diffraction. Similar 
to the wet milling process, the particle size decreased as function of the process time. Again, 
febantel showed a more profound down-sizing of the particle diameter than itraconazole. We 
also observed that the efficiency of down-sizing can be optimized by extending the residence 
time of the liquid in the flow cell by controlling the pump rate. Lower pump rates lead to longer 
residence times in the flow cell and allowed to shorten the total process time. The indirect 
sonication process clearly has the advantage that the drug is not in contact with the physical 
energy source, thus avoiding potential contamination. Furthermore, this process is expected to 
be more suitable for up-scaling, either by enlarging the flow-through cell or by putting several 
cells in series. Additionally, this process should allow working in a continuous way with constant 
in-and-out flow of fresh drug suspension, while the earlier described wet milling process is a 
batch process. Nevertheless, the indirect sonication process still suffers from relatively long, i.e. 
2h, process times that are required to significantly reduce the drug crystal size. To summarize, 
Table 2 gives an overview of the volume distributions (D values) of the drugs particles during 
processing via wet milling and indirect sonication. 
 
3.1.3 Ultrasonic melt precipitation 
 To cope with the issue of prolonged process times associated with both wet milling and 
indirect sonication, we developed a novel bottom up approach that we termed ‘ultrasonic melt 
precipitation’.  In this process, drug nanosuspensions are generated by dissolving the drug in a 
molten phase of Gelucire 44/14  at respectively 140 °C (itraconazole) and 150°C (febantel). The 
process of drug dissolution in a molten Gelucire 44/14 phase was deeper analyzed by hot stage 
microscopy and presented in Figure 6. At 60 °C a liquid Gelucire 44/14 phase exists in which the 
crystalline drug is suspended. As soon as the melting point of the respective drugs is reached, 
they dissolve in the liquid Gelucire 44/14 phase. Upon cooling to room temperature, the drug 
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(or a part of the drug) recrystallizes from the solution into very fine particles in case of febantel 
and larger precipitates in case of itraconazole, as shown in Figure 6. 
 During the ultrasonication process, the molten drug/Gelucire 44/14 mixture was 
atomized through a two-fluid nozzle into a flow cell containing water thermostatized at 10°C. 
Furthermore, during atomization of the molten drug/Gelucire 44/14 phase, cavitation is induced 
by immersion of an ultrasonic probe. After 5 min of sonication, milky suspensions of both drugs 
were obtained. Figure 3 gives a schematic representation of the experimental set-up.  
As shown in Figure 7 on the size distribution graphs, the ultrasonic melt precipitation 
approach allowed to dramatically reduce the drug particle size. Importantly, whereas wet 
milling and indirect sonication yielded a bi-modal size distribution, the ultrasonic melt 
precipitation approach resulted in a mono-modal drug nanosuspension. In case of itraconazole, 
the D(v,0.5) reduced from 20.6 µm (i.e. the crude crystalline material before melting in Gelucire 
44/14 ) to 0.51 µm, while in case of febantel the D(v,0.5) was reduced from 153.7 µm to 0.38 
µm (Table 3).  This is due to a series of events that occur during the process. First, the drug is 
dissolved in a molten Gelucire 44/14  phase through heating. Secondly, the atomisation of liquid 
Gelucire 44/14  droplets into cold water under intense cavitation induces flash precipitation of 
the drug into small crystals. Cavitation plays a crucial role in this process, preventing 
agglomeration of the newly formed crystals [29]. Indeed, when we conducted control 
experiments in absence of ultrasonication, the atomized liquid immediately gelified upon 
contact with the cold water, followed by nucleation of drug crystals and further on the 
formation of large crystalline precipitates. By contrast, performing the process under 
ultrasonication readily allowed the Gelucire 44/14  to be distributed over the whole aqueous 
phase and to control the nucleation of drug crystals, avoiding aggregation and retain the size of 
the formed drug precipitates within the nano-range. The interesting aspects of this approach 
are (1) the short processing times that are required to produce a drug suspension with a mean 
particle size below 1 µm and (2) the potential to be operated in continuous fashion. 
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3.2  In vitro drug dissolution of drug nanosuspensions 
 Finally, the itraconazole and febantel nanosuspensions were evaluated for their in vitro 
dissolution behaviour. The cumulative release curves of the respective formulations and their 
controls are shown in Figure 8. Table 4 summarizes the maximum concentration of drug that 
was dissolved after 60 min in 0.1M at 37°C. Crude drug as well as a physical mixture of drug and 
Gelucire 44/14 give very low drug concentrations, for both febantel and itraconazole. By 
contrast, the cumulative drug release curves depicted in Figure 8A, show a pronounced 
enhancement in total drug release for febantel processed via all three formulation strategies. 
Febantel formulated via ultrasonic melt precipitation achieves the highest total drug dissolved 
followed by indirect sonication and wet milling in a third place. Importantly, maximum drug 
concentration is reached within 10 min after addition of the nanosuspensions to the dissolution 
medium. In case of itraconazole only ultrasonic melt precipitation (Figure 8B) was able to 
increase drug dissolution.  
 For febantel, on the first sight, merely reducing the particle size (Figure 7) is effective to 
enhance drug dissolution, however, this is not the case for itraconazole. Probably this is due to 
the extremely poor water solubility of itraconazole, which is even several orders of magnitude 
lower than febantel that has a water. To further investigate why the ultrasonic melt 
precipitation is the only process that effectively enhances the dissolution of itraconazole we 
assessed the crystallographic state of the formulated drug by X-ray diffraction (XRD). Figure 9 
shows the corresponding X-ray diffractograms for all febantel and itraconazole formulations and 
the respective controls. These diffractograms show, relative to a physical mixture of 
drug/Gelucire 44/14 in the same ratio as used for the respective formulations, a significant 
reduction in crystallinity only for the formulations (of both drugs) that were processed via 
ultrasonic melt precipitation. The other formulations strategies had no detectable influence on 
the crystalline state of the drug. Due to the fact that febantel and itraconazole dissolve in 
Gelucire 44/14 upon heating it was found not possible to quantify via differential scanning 
calorimetry (DSC) the amount of amorphous drug that was produced during the ultrasonic melt 
crystallization process. Although, when looking at literature [30] it is clear that amorphous 
itraconazole has a much higher solubility, with values that are in the same order as those values 
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that were obtained in our present study. Hence, it is likely that ultrasonic melt precipitation 
produces a certain fraction of amorphous drug, that contributes to the observed enhanced drug 
dissolution 
 
 
 
4.  CONCLUSIONS 
 In this paper, we have evaluated several solvent-free strategies to produce micro- and 
nanosuspensions of poorly water-soluble drugs. To enhance the water-solubility of these drugs, 
Gelucire 44/14, a self-emulsifying biocompatible excipient, was used. Wet milling and indirect 
sonication yielded drug suspensions with a bimodal size distribution, comprising submicron 
particles and particles in the lower micron range. Ultrasonic melt precipitation was able to yield 
a monomodal drug suspension with submicron drug particles. All three strategies to reduce the 
size of the drug crystals in the presence of Gelucire 44/14 strongly enhanced the dissolution 
rate and total amount of dissolved drug for febantel . In case of itraconazole, only ultrasonic 
melt precipitation was able to enhance the dissolution rate and total amount of dissolved drug. 
This was attributed to the lower water solubility of itraconazole, relative to febantel, and the 
fact that ultrasonic melt precipitation produces a fraction of amorphous drug that is stabilized 
by Gelucire 44/14. 
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TABLES 
 
Table1. Composition of the crude febantel and itraconazole suspensions 
formulation 
components 
 
(wt %) (g) 
Gelucire 44/14  10,1 20 
water 75,7 150 
febantel 14,2 28,14 
Gelucire 44/14  11,5 20 
water 85,9 150 
itraconazole 2,6 4,54 
 
Table 2. Overview of the D values, measured by laser diffraction, of itraconazole and febantel drug suspension after 
different process times during respectively wet milling and indirect sonication. 
process time 
[min] 
 
 
D(v,0.1) 
[µm] 
D(v,0.5)  
[µm] 
D(v,0.9) 
[µm] 
   
 itraconazole 
milling sonication 
 
 milling sonication milling sonication milling sonication 
15 30 
 
 0.35 0.4 2.29 4.51 7.08 20.21 
30 60 
 
 0.3 0.33 1.4 2.08 4.54 6.57 
45 90 
 
 0.3 0.3 1.26 1.3 4.13 4.29 
60 120 
 
 0.29 0.28 1.07 0.96 3.66 3.36 
   
 febantel 
milling sonication 
 
 milling sonication milling sonication milling sonication 
15 30 
 
 0.29 0.89 1.53 4.1 4.11 8.95 
30 60 
 
 0.27 0.29 0.7 1.16 2.75 4.78 
45 90 
 
0.28 0.27 0.91 0.92 3.36 3.72 
60 120 
 
0.26 0.34 0.58 0.65 2.2 3.06 
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Table 3. Overview of the D values, measured by laser diffraction, of itraconazole and febantel before and after 
ultrasonic melt precipitation. 
  
D(v,0.1) 
[µm] 
D(v,0.5)  
[µm] 
D(v,0.9) 
[µm] 
  
itraconazole 
crude 
 
9.1 26 71 
processed 
 
0.26 0.51 1.25 
  
Febantel 
crude
 
36 232 480 
processed 
 
0.26 0.38 0.56 
 
 
Table 4. Maximal amount of drug dissolved within 60 min in 0.1 M HCl at 37°C obtained via the respective 
formulation strategies. 
Formulation 
 
Febantel 
[mg/ml] 
Itraconazole 
[mg/ml] 
crude drug 0.55 ± 0.05 0.0015 ± 0.001 
physical drug/Gelucire 44/14 mixture 0.8 ± 0.05 0.0028 ± 0.002 
wet milling 8.8 ± 0.5 0.0063 ± 0.001 
indirect sonication 17.45 ± 1.5 0.003 ± 0.002 
ultrasonic melt precipitation 21.3 ± 0.5 0.45 ± 0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
16 
FIGURES 
 
Figure 1. Molecular structure of (A) itraconazole and (B) febantel. 
 
 
 
Figure 2. Schematic representation of the experimental set-up for indirect sonication of drug suspensions.  (a) 
ultrasonic processor, (b) pressurized water tank, (c) security pressure valve, (d) compressed air input, (e) water 
pump, (f) syringe, (g) close cycle valve, (h) peristaltic pump, (i) sonotrode, (j) glass tube, (k) ultrasonic mini flow cell, 
(1:2) pressurized water input/output, (3;4) suspension input/output. 
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Figure 3. Schematic representation of the ultrasonic melt precipitation set-up. (a) sonotrode, (b) ultrasonic 
processor, (c) digital thermometer, (d) cooling system, (e) titanium tip, (f) booster, (g) two fluid nozzle, (h) heating 
cord, (i) temperature probe, (j) dual wall flow cell, (d1, d2) inputs for the cooling circuit. 
 
 
 
 
 
 
 
i 
j 
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Figure 4.(A) Size distribution, measured by laser diffraction, at different time points during wet milling of 
respectively itraconazole and febantel suspensions in Gelucire 44/14 . The dotted arrows indicate the ‘micro’ drug 
crystal population to diminish as function of process time in favour of the ‘nano’ population. (B) Corresponding 
evolution of the D values as a function of process time. (C) Optical microscopy images of the corresponding drug 
crystal suspensions before and after wet milling. 
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Figure 5. (A) Size distribution, measured by laser diffraction, at different time points during indirect sonication of 
respectively itraconazole and febantel suspensions in Gelucire 44/14 . The dotted arrows indicate the ‘micro’ drug 
crystal population to diminish as function of process time in favour of the ‘nano’ population. (B) Corresponding 
evolution of the D values as a function of process time. (C) Optical microscopy images of the corresponding drug 
crystal suspensions before and after indirect sonication. 
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Figure 6. Optical microscopy images recorded using a hot stage microscopy set-up, demonstrating the dissolution 
of febantel, respectively itraconazole in a liquid Gelucire 44/14 phase as soon as the melting point of the drug is 
reached. The panels a, b and c show images at 10 s time intervals. Upon cooling to room temperature, (partial) re-
crystallization occurs.  
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Figure 7. Size distribution, measured by laser diffraction, of the drug (itraconazole, respectively febantel) crystals in 
crude state (red curves) and after ultrasonic melt precipitation. 
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 Figure 8. Cumulative in vitro in 0.1 M HCl at 37 °C release of (A) febantel and (B) itraconazole formulated via either 
wet milling, indirect sonication or melt precipitation. As controls, crude unprocessed drug and a physical mixture of 
drug and Gelucire 44/14  were taken. 
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Figure 9.  X-Ray diffractograms of the respective (A) febantel and (B) itraconazole formulations. 
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